Aerie Pharmaceuticals
Investor Relations Department
135 US Highway 206, Suite 15
Bedminster, NJ 07921
United States

Visit IR website
Sign-up for Email alerts

NASDAQ: AERI	
Last Trade:	45.23
Trade Time:	12:24 PM ET Mar 30, 2017
Change:	-0.03 (-0.055%)
Day Range	45.00 - 45.55
52-Week Range	11.89 - 51.85
Volume	68,083

Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

We are a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of patients with glaucoma and other diseases of the eye.

Glaucoma is a progressive and highly individualized disease, in which elevated levels of intraocular pressure, or IOP, are associated with damage to the optic nerve, which results in irreversible vision loss and potentially blindness. Patients may suffer the adverse effects of glaucoma across a wide range of IOP levels. Our product candidates, Rhopressa™ (netarsudi... (more)

Stock Performance

Press Releases [View all]

Mar 28, 2017
Aerie Pharmaceuticals to Present at the 16th Annual Needham Healthcare Conference

Mar 7, 2017
Aerie Pharmaceuticals Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Business Update

Mar 2, 2017
Aerie Pharmaceuticals to Present at Three Investor Conferences in March

Mar 1, 2017
Aerie Pharmaceuticals Announces Resubmission of NDA for RhopressaTM (netarsudil ophthalmic solution) 0.02%

Feb 27, 2017
Aerie Pharmaceuticals to Announce Fourth Quarter and Year End 2016 Financial Results and Host Conference Call on Tuesday, March 7, 2017

Upcoming Events [View all]

Apr 4, 2017 1:40 PM ET
The 16th Annual Needham Healthcare Conference

Financials [View all]

Fourth Quarter Financial Results

Mar 9, 2017
Annual Report (10-K)

Apr 29, 2016
Proxy Statement (DEF 14A)

Nov 3, 2016
Quarterly Report (10-Q)

Aug 4, 2016
Quarterly Report (10-Q)

May 3, 2016
Quarterly Report (10-Q)